Calamos Advisors LLC Has $2.31 Million Position in Insmed, Inc. $INSM

Calamos Advisors LLC decreased its holdings in shares of Insmed, Inc. (NASDAQ:INSM) by 99.8% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 22,952 shares of the biopharmaceutical company’s stock after selling 14,043,349 shares during the period. Calamos Advisors LLC’s holdings in Insmed were worth $2,310,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Adage Capital Partners GP L.L.C. increased its position in shares of Insmed by 109.2% during the first quarter. Adage Capital Partners GP L.L.C. now owns 3,446,944 shares of the biopharmaceutical company’s stock worth $262,967,000 after acquiring an additional 1,799,382 shares in the last quarter. Nuveen LLC bought a new position in Insmed in the 1st quarter valued at about $88,351,000. 1832 Asset Management L.P. acquired a new position in Insmed during the 1st quarter valued at about $37,214,000. Wellington Management Group LLP increased its holdings in Insmed by 62.5% during the 1st quarter. Wellington Management Group LLP now owns 1,222,627 shares of the biopharmaceutical company’s stock worth $93,274,000 after purchasing an additional 470,401 shares in the last quarter. Finally, Westfield Capital Management Co. LP raised its stake in shares of Insmed by 49.9% in the first quarter. Westfield Capital Management Co. LP now owns 1,406,609 shares of the biopharmaceutical company’s stock worth $107,310,000 after purchasing an additional 468,058 shares during the last quarter.

Insider Buying and Selling

In related news, CEO William Lewis sold 6,865 shares of the company’s stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $128.40, for a total value of $881,466.00. Following the transaction, the chief executive officer owned 233,924 shares in the company, valued at approximately $30,035,841.60. This represents a 2.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Melvin Md Sharoky sold 10,000 shares of the firm’s stock in a transaction on Friday, September 12th. The stock was sold at an average price of $145.39, for a total value of $1,453,900.00. Following the completion of the sale, the director directly owned 262,675 shares of the company’s stock, valued at $38,190,318.25. This represents a 3.67% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 179,787 shares of company stock worth $26,428,149 in the last three months. Insiders own 3.00% of the company’s stock.

Analysts Set New Price Targets

INSM has been the subject of several recent research reports. TD Cowen upped their price target on Insmed from $154.00 to $193.00 and gave the stock a “buy” rating in a report on Thursday, October 2nd. Bank of America upped their target price on shares of Insmed from $142.00 to $187.00 and gave the stock a “buy” rating in a research note on Monday, October 27th. Wells Fargo & Company raised their price target on shares of Insmed from $171.00 to $217.00 and gave the company an “overweight” rating in a research report on Friday, October 31st. Truist Financial upped their price objective on shares of Insmed from $126.00 to $139.00 and gave the stock a “buy” rating in a research report on Thursday, August 14th. Finally, Mizuho set a $196.00 price objective on shares of Insmed in a research note on Wednesday, October 29th. Nineteen investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $173.29.

Insmed Price Performance

INSM opened at $190.96 on Friday. The firm has a market cap of $40.73 billion, a P/E ratio of -33.44 and a beta of 1.05. The firm has a 50-day moving average of $161.39 and a 200 day moving average of $119.49. The company has a debt-to-equity ratio of 0.45, a quick ratio of 6.33 and a current ratio of 6.68. Insmed, Inc. has a fifty-two week low of $60.40 and a fifty-two week high of $197.08.

Insmed (NASDAQ:INSM) last announced its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported ($1.75) EPS for the quarter, missing the consensus estimate of ($1.35) by ($0.40). The company had revenue of $142.34 million during the quarter, compared to the consensus estimate of $114.33 million. Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%.The business’s revenue was up 52.4% on a year-over-year basis. During the same period in the prior year, the firm posted ($1.27) EPS. Insmed has set its FY 2025 guidance at EPS. On average, research analysts expect that Insmed, Inc. will post -4.56 EPS for the current year.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.